Abstract
Alzheimers disease (AD) is a major neurodegenerative disease that affects mainly people over 65 years of age. The main therapeutic approach to AD is based on the use of acetylcholinesterase (AChE) inhibitors. Recent studies have shown that butyrylcholinesterase (BuChE) can also be considered an attractive target for the development of novel drugs for AD therapy. The design of new potent and selective BuChE inhibitors is of great importance in drug discovery. 2D quantitative structure-activity relationship studies were conducted on a series of potent inhibitors of human BuChE using classical and hologram QSAR (HQSAR) approaches. A training set of 40 compounds was employed to derive the models. Classical QSAR models showed moderate correlation (r2 = 0.836, q2 = 0.750), with no substantial predictive power for untested compounds. On the other hand, the best HQSAR model (r2 = 0.928, q2 = 0.723) was used to predict the potency of 10 test set compounds, and the predicted values were in good agreement with the experimental results, showing the potential of this model for new untested compounds.
Keywords: 2D QSAR, HQSAR, Alzheimer, Tacrine derivatives, Butyrylcholinesterase, Inhibitors
Letters in Drug Design & Discovery
Title: Classical and Hologram QSAR Studies on a Series of Tacrine Derivatives as Butyrylcholinesterase Inhibitors
Volume: 4 Issue: 2
Author(s): M. S. Castilho, R. V. C. Guido and A. D. Andricopulo
Affiliation:
Keywords: 2D QSAR, HQSAR, Alzheimer, Tacrine derivatives, Butyrylcholinesterase, Inhibitors
Abstract: Alzheimers disease (AD) is a major neurodegenerative disease that affects mainly people over 65 years of age. The main therapeutic approach to AD is based on the use of acetylcholinesterase (AChE) inhibitors. Recent studies have shown that butyrylcholinesterase (BuChE) can also be considered an attractive target for the development of novel drugs for AD therapy. The design of new potent and selective BuChE inhibitors is of great importance in drug discovery. 2D quantitative structure-activity relationship studies were conducted on a series of potent inhibitors of human BuChE using classical and hologram QSAR (HQSAR) approaches. A training set of 40 compounds was employed to derive the models. Classical QSAR models showed moderate correlation (r2 = 0.836, q2 = 0.750), with no substantial predictive power for untested compounds. On the other hand, the best HQSAR model (r2 = 0.928, q2 = 0.723) was used to predict the potency of 10 test set compounds, and the predicted values were in good agreement with the experimental results, showing the potential of this model for new untested compounds.
Export Options
About this article
Cite this article as:
Castilho S. M., C. Guido V. R. and Andricopulo D. A., Classical and Hologram QSAR Studies on a Series of Tacrine Derivatives as Butyrylcholinesterase Inhibitors, Letters in Drug Design & Discovery 2007; 4 (2) . https://dx.doi.org/10.2174/157018007779422505
DOI https://dx.doi.org/10.2174/157018007779422505 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modeling Rett Syndrome Using Human Induced Pluripotent Stem Cells
CNS & Neurological Disorders - Drug Targets Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Inhibitors of Glycine Transporter-1: Potential Therapeutics for the Treatment of CNS Disorders
Current Topics in Medicinal Chemistry Revolutionary Impact of Nanodrug Delivery on Neuroscience
Current Neuropharmacology Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Development of Pramipexole Hydrochloride Nanocrystals and their Characterization based on <I>In vitro</I> Dissolution Studies
Current Nanomedicine Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Recent Developments in Therapeutic Approaches for Lysosomal Storage Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Commentary: Multifactoriality of Amytrophic Lateral Sclerosis: Linking Unfolded Proteins to Oxidative Stress in Microglia
CNS & Neurological Disorders - Drug Targets The Double-Edged Nature of Recovery in First-Episode Psychosis
Current Psychiatry Reviews Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Nitric Oxide Related Therapeutic Phenomenon: A Challenging Task
Current Pharmaceutical Design Separating Fact from Fiction: Assessing the Potential of Modified Adenovirus Vectors for Use in Human Gene Therapy
Current Gene Therapy Recent Advances in the Rationale Design of GPER Ligands
Current Medicinal Chemistry Recent Finding in Repair of the Peripheral Nerve Lesions Using Pharmacological Agents: Common Methods for Evaluating the Repair Process
Central Nervous System Agents in Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Unraveling the Structural Requirements of Chalcone Chemistry Towards Monoamine Oxidase Inhibition
Central Nervous System Agents in Medicinal Chemistry Cordycepin Exerts Neuroprotective Effects via an Anti-Apoptotic Mechanism based on the Mitochondrial Pathway in a Rotenone-Induced Parkinsonism Rat Model
CNS & Neurological Disorders - Drug Targets